Xenon Pharmaceuticals Inc XENE

$35.34 -1.16 (-3.18%)

Valuation

Market cap
3,528,309,000
Revenue TTM
$7,500,000
Net income TTM
$-345,910,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,612.13%
Debt to equity
0.00

Trading

Volume
636,500
Avg volume
1,694,026
Day's range
$35.23 – $36.62
Shares out
96,666,000
Stochastic %K
54%
Beta
0.60
Analysts
Strong Sell
Price target
$71.66

Price

Company profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary genera...

Show more

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 484 3300
Website
https://www.xenon-pharma.com
Address
200-3650 Gilmore Way, Burnaby, Canada

Latest news

Stocktwits

Laei Oct 19, 8:20 PM
$XENE Co-founder Simon Pimstone stepped down as CEO in 2021 and left the board in 2024. Form 4s show he exercised options and sold shares around $38-40 in 2023. It puzzles me that he sold shares and left if he truly believes in the science he built. Does anyone know if he still holds a meaningful stake, or why he left? Not advice, just curious.
0 replies
usedgum Oct 19, 8:08 PM
$XENE
0 replies
SuperGreenToday Oct 17, 2:49 AM
$XENE Share Price: $33.51 Contract Selected: Apr 16, 2027 $30 Calls Buy Zone: $4.42 – $5.46 Target Zone: $7.14 – $8.73 Potential Upside: 53% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
MooseG Oct 16, 5:33 PM
$XENE maybe its now attractive for the epilepsy asset at these prices. Trading like they have nothing else.
0 replies
Stocktwits52wLows Oct 16, 2:30 PM
$XENE printed a new 52-week low today
0 replies
Crazycracker Oct 16, 1:40 PM
$XENE
0 replies
usedgum Oct 14, 3:48 PM
$XENE she did not tell me my GME would outperform this over the past week or so. Hmmmm. At least my GME tickets are green. She still likes it apparently just not sure when it turns around!
0 replies
Crazycracker Oct 13, 6:56 PM
$XENE taking a beating on this on
0 replies